Aberrant promoter CpG methylation and its translational applications in breast cancer
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Breast cancer is a complex disease driven by multiple factors including both genetic and epigenetic alterations. Recent studies revealed that abnormal gene expression induced by epigenetic changes, including aberrant promoter methylation and histone modification, plays a critical role in human breast carcinogenesis. Silencing of tumor suppressor genes (TSGs) by promoter CpG methylation facilitates cells growth and survival advantages and further results in tumor initiation and progression, thus directly contributing to breast tumorigenesis. Usually, aberrant promoter methylation of TSGs, which can be reversed by pharmacological reagents, occurs at the early stage of tumorigenesis and therefore may serve as a potential tumor marker for early diagnosis and therapeutic targeting of breast cancer. In this review, we summarize the epigenetic changes of multiple TSGs involved in breast pathogenesis and their potential clinical applications as tumor markers for early detection and treatment of breast cancer.
著者Xiang T.X., Yuan Y., Li L.L., Wang Z.H., Dan L.Y., Chen Y., Ren G.S., Tao Q.
期刊名稱Chinese Journal of Cancer
詳細描述In press.
出版年份2013
月份1
日期17
卷號32
期次1
出版社BioMed Central
出版地United States
頁次12 - 20
國際標準期刊號1000-467X
電子國際標準期刊號1944-446X
語言英式英語
關鍵詞Breast cancer, CpG, Methylation, Tumor marker, Tumor suppressor gene

上次更新時間 2020-26-11 於 02:31